21 August,2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

**PPMX-T003: Publication of a Preclinical Study on an Anti-Transferrin Receptor 1 Antibody for Colorectal Cancer Metastasis**

Perseus Proteomics Inc. (the "Company") hereby announces that research findings on PPMX-T003, the Company's anti-transferrin receptor 1 (TfR1) antibody currently under development, have been published online in the academic journal *Signal Transduction and Targeted Therapy*. The findings were obtained through the joint research project "Investigation of the Therapeutic Effects of Cancer-Specific Antibodies in Solid Tumor Models" conducted by the Company and Gunma University.

Distant metastasis is a major cause of death in colorectal cancer, and effective targeted therapies are needed. This study is the first to show, using PPMX-T003, an antibody that specifically recognizes TfR1, that TfR1 — which is highly expressed in colorectal cancer and plays an important role in cellular iron uptake — is a promising therapeutic target.

In this study, administration of PPMX-T003 suppressed tumor growth in a mouse model implanted with patient-derived colorectal cancer. Furthermore, PPMX-T003 was shown to prevent the development of liver metastases of colorectal cancer. PPMX-T003 was also evaluated in gastric cancer models, where it similarly prevented the development of peritoneal dissemination, a condition in which cancer spreads throughout the abdominal cavity. In addition, repeated administration of PPMX-T003 to mice with peritoneal dissemination of gastric cancer resulted in a substantial extension of survival.

These results provide preclinical evidence that TfR1 may serve as a therapeutic target in colorectal and gastric cancers. They also suggest that PPMX-T003 has the potential not only to suppress primary tumor growth but also to help prevent metastasis and dissemination.

**Publication Information**

**Title**: "Clinical-stage human anti-transferrin receptor antibody suppresses colorectal cancer metastasis"

**Journal**: *Signal Transduction and Targeted Therapy*

**Authors**: Mizuki Endo[1], Takuya Shiraishi[1], Takehiko Yokobori[2], Hiroshi Saeki[1], Ken Shirabe[3], Tadashi Matsuura[4], et al.

1. Department of Gastrointestinal Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University
2. Division of Gene Therapy Science, Gunma University Initiative for Advanced Research (GIAR)
3. Department of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University
4. Perseus Proteomics Inc.

**Publication date**: 20 August,2026 (published online)

**URL**: https://doi.org/10.1038/s41392-026-02917-9